SecBot SecBot
8-K ·Filed Nov 4, 2026

PSNL

Personalis, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed12d 8h ago SEC0001193125-26-447196
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The pending Tempus acquisition dominates the stock's trajectory; this earnings release is largely backward-looking with no guidance. Monitor the merger proxy/prospectus (S-4) for shareholder vote timing and any termination risk. The strong clinical revenue growth trajectory supports the strategic rationale for the deal.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$15.55
T+0 close · Nov 4, 2026 · via day close
Latest settled
+1.99%
T+5 · $15.86 · next T+20 in 17d
Vs SPY
−1.30%
α at T+5
Latest observation
−2.97%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $15.55entry
  2. T+1 · 11d ago +1.54%α +1.23% · $15.79
  3. T+5 · 5d ago +1.99%α −1.30% · $15.86
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Personalis reported Q3 2026 total revenue of $25.6M, up 77% YoY from $14.5M, driven by clinical test revenue surging to $4.4M from $0.4M and population sequencing revenue of $4.0M vs $0.2M. Net loss widened to $33.8M from $21.7M, with SG&A expense doubling to $26.0M largely due to merger-related costs. The company withdrew guidance and will not hold an earnings call due to the pending Tempus acquisition announced July 20, 2026.

Key Financial Metrics

Revenue
$25.6M
est $21.3M · +20.2% · +76.6% YoY

Key Facts

  • Total revenue $25.6M vs $14.5M YoY (+77%)
  • Clinical test revenue $4.4M vs $0.4M YoY, volume 13,157 tests vs 4,388
  • Pharma testing services revenue $17.1M vs $13.1M YoY
  • Population sequencing (VA MVP) revenue $4.0M vs $0.2M YoY
  • SG&A expense $26.0M vs $13.0M YoY, including $4.8M related party sales/marketing
  • Cash and investments $190.6M at quarter end
  • Guidance withdrawn due to pending Tempus acquisition

Financial Impact

Revenue beat consensus by $4.3M (20.2%); EPS miss by $0.07 (28% worse than consensus); operating loss widened $12.2M YoY

revenueepsoperating losssg&a expense

Segment Breakdown

SegmentRevenueGrowth
Pharma testing services$17.1M+30.3%
Enterprise sales$8.0K-98.8%
Population sequencing$4.1M+1638.0%
Clinical diagnostic$4.4M+1039.1%
Other$33.0K-63.3%

Risk Factors

  • Merger may not close if shareholders do not approve or conditions are not satisfied
  • Operating losses continue to widen with SG&A costs elevated
  • No forward guidance provided, reducing visibility
  • Potential litigation related to the merger

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
55% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-447196
Document: psnl-20261104.htm0001193125-26-447196
Document: 0001193125-26-447196-index-headers.html0001193125-26-447196
Document: 0001193125-26-447196-index.html0001193125-26-447196
Document: 0001193125-26-447196.txt0001193125-26-447196
8-K Data (Synthetic)0001193125-26-447196

Track record

29 reports on PSNL

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +18.82% at T+60 after the Jul 20, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.16 Now $14.80 −2.34% settles Feb 12
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $15.71 Now $14.80 −5.79% settles Feb 11
  3. Nov 12, 20264d ago 425 Neutral 4/10 Entry $15.86 Now $14.80 −6.68% settles Feb 10
  4. Nov 6, 202610d ago 425 Neutral 3/10 Entry $15.95 Now $14.80 −7.21% settles Feb 5
  5. Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $15.55 Now $14.80 −4.82% settles Feb 3
  6. Nov 3, 202613d ago 425 Neutral 3/10 Entry $15.79 Now $14.80 −6.27% settles Feb 2
  7. Oct 30, 202617d ago 425 Neutral 4/10 Entry $15.76 Now $14.80 −6.09% settles Jan 29
  8. Oct 21, 202626d ago DEFM14A Neutral 5/10 Entry $15.82 Now $14.80 −6.45% settles Jan 20
  9. Oct 20, 202627d ago 425 Neutral 4/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
  10. Oct 20, 202627d ago 425 Neutral 5/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
Showing 10 of 29

US Market Status

Market Closed · Opens in 8h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026